Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis
Status:
Not yet recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
For patients with unresectable colorectal cancer liver metastases, preclinical studies have
shown that after the resistance of cetuximab, the treatment sensitivity can be restored by
stopping cetuximab for a period of time. This is called the cetuximab re-challenge. And the
circulating tumor DNA (ctDNA) test is reported a biomarker for the efficacy of cetuximab
rechallenge. However, there is still no randomized controlled trial for verification. This
study aims at patients after the first-line treatment of cetuximab has progressed. After the
second-line non-cetuximab treatment has progressed, the effects of re-application of combined
with cetuximab and chemotherapy alone are compared to verify the re-challenge effect.